Welcome to our dedicated page for AWAKN LIFE SCIENCES news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on AWAKN LIFE SCIENCES stock.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on developing medication-assisted treatments for addiction, particularly Alcohol Use Disorder (AUD). The company recently completed an investigative study on the dissociative effects of a proprietary S-ketamine formulation, administered orally. This study showed promising results, leading to the designation of program AWKN-002 for AUD treatment in the US market. Awakn has also entered into global licensing agreements and partnerships to advance its innovative therapies.
Rhea-AI Summary
Awakn Life Sciences Corp. is facing a potential cease-trade order due to the late filing of its audited annual financial statements and MD&A for the financial year ended January 31, 2024. The company delisted its common shares from Cboe Canada and listed them on the Canadian Securities Exchange, resulting in a condensed timeline for filing. If the financial statements are not filed by May 7, 2024, a cease-trade order may be issued by the Ontario Securities Commission. Awakn has applied for a management cease trade order to allow non-directors, officers, and insiders to continue trading in their securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. has closed the first tranche of a private placement, raising $131,428 through the issuance of 285,714 units at $0.46 per unit. The funds will be used for general working capital. The offering is subject to regulatory approvals and securities legislation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.66%
Tags
-
News
Rhea-AI Summary
Awakn Life Sciences Corp. announces a Licensing Partnership with Rivus Wellness and Research Institute for its proprietary treatment protocol, Awakn Kare, targeting Alcohol Use Disorder. The agreement aims to improve addiction treatment success rates in the U.S. southern states. Additionally, Awakn discloses details of a non-brokered private placement financing for gross proceeds of up to $4,000,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
Rhea-AI Summary
Awakn Life Sciences Corp. (AWKNF) has received approval to list its common shares on the Canadian Securities Exchange under the symbol 'AWKN' with a focus on developing medication-assisted treatments for Alcohol Use Disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.37%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. is set to list its common shares on the Canadian Securities Exchange (CSE) after receiving conditional approval, with the intention to delist from Cboe Canada. The company has also closed the fifth tranche of a non-brokered private placement financing, issuing 142,857 units for gross proceeds of $65,714 for this tranche and $3,030,377 in total for the Offering to date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. has designated program AWKN-002 for Alcohol Use Disorders in the US market, focusing on a proprietary S-ketamine formulation administered sublingually via an oral thin film. The company has successfully completed an investigative study on the dissociative effect and reduction in alcohol cravings of the S-ketamine OTF, leading to the designation of AWKN-002. Additionally, Awakn has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine OTF, ensuring strong intellectual property protection and potential to rapidly progress to late clinical stage trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.17%
Tags
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine formulation to treat addiction, anxiety, and eating disorders. The agreement includes exclusive rights, access to Phase 1 data, and patents filed in the US and key international markets. The sublingual S-ketamine formulation offers potential advancements in addiction treatment, with faster onset of action, precise dosing, and reduced adverse effects. The agreement also includes terms related to milestone payments, royalties, and commercial manufacturing of the drug product by LTS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces recent corporate updates, including regulatory approval for a phase III clinical trial for its lead program AWKN-P001 for the treatment of Severe Alcohol Use Disorder, completion of a feasibility study for its proprietary formulation of MDMA, and engagement with Orphan Insight Ltd. to develop market access for its lead program. The company also closed the fourth tranche of a private placement financing for gross proceeds of $230,000 and $2,964,663 in total for the Offering to date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces clinical trial authorization from the MHRA and ethical approval from the Health Research Authority in the UK for a phase III clinical trial for its lead program AWKN-P001, a N-methyl-D-aspartate receptor-modulating drug used in combination with psycho-social support to treat Severe Alcohol Use Disorder (SAUD). The trial will be funded by Awakn, The University of Exeter, and a partnership between the NIHR and the MRC. Enrollment for the phase III is due to start in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) receives notice of non-compliance from Cboe Canada regarding its common stock listing, with 90 days to address the issue. The notice does not impact the company's operations or its focus on advancing psychedelic research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.91%
Tags
FAQ
What is the current stock price of AWAKN LIFE SCIENCES (AWKNF)?
The current stock price of AWAKN LIFE SCIENCES (AWKNF) is $0.0777 as of October 15, 2024.
What is the market cap of AWAKN LIFE SCIENCES (AWKNF)?
The market cap of AWAKN LIFE SCIENCES (AWKNF) is approximately 3.2M.
What is Awakn Life Sciences Corp. focused on?
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing medication-assisted treatments for addiction, with a particular emphasis on Alcohol Use Disorder (AUD).
What recent study did Awakn complete?
Awakn recently completed an investigative study on the dissociative effects of a proprietary S-ketamine formulation administered orally, showing promising results.
What program did Awakn designate for AUD treatment in the US market?
Awakn designated program AWKN-002, involving S-ketamine OTF plus manualized relapse prevention cognitive-behavioral therapy (CBT), for AUD treatment in the US market.
What global licensing agreements has Awakn entered into?
Awakn has entered into global licensing agreements, including one with LTS Lohmann Therapie-Systeme AG, for a proprietary S-ketamine OTF.
What is the strategic focus of Awakn in commercializing its R&D pipeline?
Awakn's strategy is focused on commercializing its R&D pipeline across multiple channels to provide breakthrough therapeutics for addiction sufferers.
What is the goal of Awakn's treatment approach?
Awakn aims to offer efficient and effective treatment options to improve the performance of the addiction industry and provide better outcomes for those suffering from addiction.
Who is Awakn partnering with in the US for treatment expansion?
Awakn has partnered with Rivus Wellness and Research Institute in Oklahoma City to expand treatment options for individuals in need of addiction therapy.
What is the financial status of Awakn?
Awakn has recently closed multiple financing tranches, including private placements and intends to file its annual financial statements by May 30, 2024.
What steps is Awakn taking to address filing delays?
Awakn has applied for a management cease-trade order to address the delayed filing of its financial statements, ensuring transparency and compliance with regulatory requirements.
What information will Awakn provide during the filing delay period?
During the filing delay, Awakn will issue bi-weekly default status reports to keep investors and stakeholders informed about the company's status and developments.
AWAKN LIFE SCIENCES CORP